Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf Sells 200,000 Shares

Organogenesis (NASDAQ:ORGO) Director Glenn Nussdorf sold 200,000 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the transaction, the director owned 2,565,591 shares in the company, valued at $13,187,137.74. This represents a 7.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Organogenesis Stock Up 9.5%

Organogenesis stock traded up $0.50 during trading hours on Thursday, hitting $5.77. The company had a trading volume of 1,260,179 shares, compared to its average volume of 1,452,672. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $7.08. The firm’s fifty day moving average is $4.81 and its 200-day moving average is $4.48. The firm has a market capitalization of $732.27 million, a P/E ratio of -48.08 and a beta of 1.47.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. The firm had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. On average, research analysts forecast that Organogenesis will post -0.07 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning increased its stake in shares of Organogenesis by 8.2% in the third quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after buying an additional 2,887 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Organogenesis by 57.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock worth $61,000 after buying an additional 5,273 shares in the last quarter. Quarry LP bought a new stake in Organogenesis during the 3rd quarter worth about $25,000. State of Alaska Department of Revenue bought a new position in shares of Organogenesis in the third quarter worth about $25,000. Finally, Farther Finance Advisors LLC bought a new position in shares of Organogenesis in the second quarter worth about $35,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ORGO has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $9.00 price target on shares of Organogenesis in a research report on Monday. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a research report on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.